L01FX06 · Antineoplastic and immunomodulating agents
Oportuzumab monatox DLRC Pharma Services
Indications
Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high grade Ta and/or T1 papillary tumours
Composition
- Active substance
- oportuzumab monatox
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Oportuzumab monatox DLRC Pharma Services
- Active substance
- oportuzumab monatox
- ATC code
- L01FX06
- Therapeutic area
- Urologic Neoplasms, Urinary Bladder Neoplasms
- Marketing authorisation holder
- DLRC Pharma Services Ltd